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Abstract
Background: Diverse clinical features have been reported in human African trypanosomiasis (HAT) foci caused by
Trypanosoma brucei rhodesiense (T.b.rhodesiense) giving rise to the hypothesis that HAT manifests as a chronic disease in
South-East African countries and increased in virulence towards the North. Such variation in disease severity suggests there
are differences in host susceptibility to trypanosome infection and/or genetic variation in trypanosome virulence. Our
molecular tools allow us to study the role of host and parasite genotypes, but obtaining matched extensive clinical data
from a large cohort of HAT patients has previously proved problematic.
Methods/Principal Findings: We present a retrospective cohort study providing detailed clinical profiles of 275 HAT
patients recruited in two northern foci (Uganda) and one southern focus (Malawi) in East Africa. Characteristic clinical signs
and symptoms of T.b.rhodesiense infection were recorded and the degree of neurological dysfunction determined on
admission. Clinical observations were mapped by patient estimated post-infection time. We have identified common
presenting symptoms in T.b.rhodesiense infection; however, marked differences in disease progression and severity were
identified between foci. HAT was characterised as a chronic haemo-lymphatic stage infection in Malawi, and as an acute
disease with marked neurological impairment in Uganda. Within Uganda, a more rapid progression to meningo-encephaltic
stage of infection was observed in one focus (Soroti) where HAT was characterised by early onset neurodysfunction;
however, severe neuropathology was more frequently observed in patients in a second focus (Tororo).
Conclusions/Significance: We have established focus-specific HAT clinical phenotypes showing dramatic variations in
disease severity and rate of stage progression both between northern and southern East African foci and between Ugandan
foci. Understanding the contribution of host and parasite factors in causing such clinical diversity in T.b.rhodesiense HAT has
much relevance for both improvement of disease management and the identification of new drug therapy.
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Introduction
Human African trypanosomiasis is caused by infection with
African trypanosomes, which are transmitted by the haematoph-
agous tsetse fly. Trypanosoma brucei gambiense (T.b. gambiense) HAT is
present in West and Central Africa and T.b. rhodesiense HAT is
found in East and Southern Africa. The disease is characterised by
two stages, the early or haemo-lymphatic stage where trypano-
somes proliferate at the bite site, travel to local lymph nodes and
establish infection in the bloodstream, and the late or meningo-
encephalitic stage in which trypanosomes invade the central
nervous system (CNS) leading to coma and death if untreated
[1,2]. HAT has a severe social and economic impact across sub-
Saharan Africa today with an estimated 60 million people at risk
of African trypanosome infection and 70,000 people are infected
[3].
T.b. rhodesiense infection is typically described as an acute disease
with rapid progression to late stage infection, however, a wide
range of disease pathologies have been reported for many years in
East Africa from asymptomatic carriers and mild chronic
infections with incubation times of several months in Zambia
[4,5,6,7] to accounts of acute infections causing severe disease
pathology within 4–6 weeks [8] and 80% of deaths within 6
months [9] in the Busoga focus of Uganda/Kenya. Analysis of
historic T.b. rhodesiense epidemics in East Africa led to the proposal
that HAT spread from Zambia to Tanzania and Uganda
increasing in acuteness and virulence towards the north [10].
However, this is unlikely as T.b. rhodesiense, not T.b. gambiense,i s
now thought to be responsible for the first recorded HAT
epidemic in 1900 which occurred in the Busoga focus [11,12].
Variation in HAT disease severity between foci suggests that there
is genetic variation in trypanosome virulence and/or differences in
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analysis of T.b. rhodesiense isolates from the Busoga focus and the
Luangwa Valley focus in Zambia have confirmed distinct parasite
genotypes between northern and southern East African HAT foci
[13,14,15]. Correlation of parasite genotypes with different clinical
profiles, however, is limited although analysis of a small number of
T.b. rhodesiense isolates from within the Busoga focus (1989 to 1993)
identified two main zymodemes (the ‘busoga’ and ‘zambezi’
zymodemes), which were associated with different clinical
manifestations [16]. There is also evidence for differences in host
susceptibility to T.b. rhodesiense infection. In Zambia different
clinical profiles were associated with tribal group and previous
HAT exposure [6,4]. In addition, there are accounts of acute
disease pathology in non-local individuals with HAT compared to
the typically chronic disease described in Zambian patients
[4,17,6,7,18,19].
Recently we reported dramatic variation in disease severity
between northern and southern East African HAT patients in
Uganda and Malawi respectively [20]. HAT patients recruited in
Soroti and Tororo foci in East (E) Uganda followed an acute
disease course with progression to meningo-encephalitic infection
in 87% of patients. In contrast, HAT cases from the Nkhotakota
district Central (C) Malawi presented with a mild disease and
trypanosome CNS invasion was only diagnosed in 7% of recruits
even after several months’ incubation. These disease phenotypes
were associated with both different host inflammatory cytokine
responses and different parasite serum resistance associated (SRA)
gene polymorphisms. In addition, differences in disease pathology
were also observed between HAT cases recruited in two
geographically close foci (Tororo and Soroti) within Eastern
Uganda [21]. A higher proportion of Tororo focus HAT cases had
progressed to CNS infection, displayed more severe neurological
dysfunction and higher plasma IFN-c production than Soroti focus
cases. Trypanosome isolates were found to be genetically distinct,
thus, demonstrating that distinct parasite genotypes circulating in
the field in spatially separated foci within Uganda are associated
with differences in virulence. We also hypothesised that the
magnitude of host systemic IFN-c production determines the post-
infection time at which trypanosomes invade the CNS in acute
HAT, while the ‘mild’ and ‘severe’ phenotypes specific to northern
and southern East African foci, which are geographically much
further apart, involve differing abilities to down-regulate TNF-a
mediated pathology by TGF-b.
These studies suggest that both genetic variation in T.b.
rhodesiense virulence and differences in host resistance to infection
play key roles in HAT disease severity. To examine the influence
of parasite and host genetics on HAT severity within and between
foci it is essential to determine clinical profiles for HAT in
southern and northern East African foci. Here we present an
extensive clinical study of T.b. rhodesiense HAT in two northern and
one southern East African foci (Figure 1). The two northern
(Uganda) foci are 150 km apart and are referred to as Tororo and
Soroti foci. The Tororo focus is part of the historic Busoga focus,
while HAT cases were first detected in the Soroti focus in
December 1998 [22,23]. G.f. fuscipes is the vector for transmission
in both ‘northern’ foci. The ‘southern’ focus was Nkhotakota
district of C Malawi. Sleeping Sickness has been recorded here
since 1911 and is it associated with transmission by G.m. morsitans
and G. pallidipes in the Nkhotakota Wildlife Reserve and the
Kasungu National Park [24,25]. We have documented detailed
clinical histories of each patient, recorded HAT signs and
symptoms on admission, analysed the rate of stage progression,
determined parasite burden and CSF WBC counts, and assessed
the influence of co-infections on HAT clinical profiles.
Materials and Methods
Study sites and patient recruitment
Recruitment and diagnosis. This was a site-specific
retrospective cohort study. 275 HAT patients were recruited in
two northern East African foci (E Uganda and SE Uganda/
Kenyan border region), and one southern East African focus (C
Malawi) (Figure 1). HAT patient recruitment periods in SE
Uganda/Kenyan border focus covered October 1998 to March
1999, June 1999 to September 2000 and July 2002 to July 2003; in
E Uganda recruitment began after diagnosis of the first case in this
region in December 1998 to March 1999, April 2000 to
September 2000, and August 2002 to August 2003; in C Malawi
cases were recruited from February 2002 until December 2002. As
all HAT cases diagnosed during the defined study periods were
recruited (with the exception of 10 cases due to co-infections) they
represent an accurate cross section and there is no sample bias.
Observation bias is minimised as all individuals are confirmed
HAT cases (this is an absolute diagnosis not prone to bias), and
clinical parameters are recorded on a standardised patient
recruitment form.
During study periods, all HAT patients attended Livestock
Health Research Institute (LIRI) hospital SE Uganda (0u429170N,
34u109230E), Serere Health Centre E Uganda, (1u319200N,
33u269490E), or Nkhotakota hospital C Malawi (12u579420N,
34u149050E). These included individuals who self-reported for
diagnosis and individuals who had been identified during field
surveillance in areas with known tsetse and/or HAT problems. In
both cases initial diagnosis involved microscopic examination of
wet and thick blood films [26,27] or the buffy coat region after
microhaematocrit centrifugation (mHCT) [28,29] prepared from
finger prick blood. Parasitemia was recorded as the number of
parasites observed in 10 fields at 4006magnification.
Clinical observations. On admission a comprehensive
clinical history was taken and a physical examination performed
on all HAT patients. All clinical examinations were performed by
Author Summary
T. b. gambiense and T. b. rhodesiense cause human African
trypanosomiasis (HAT). These parasite subspecies differ in
their rate of progression to central nervous system (CNS)
infection, and consequently to coma and death. Variation
in disease progression and severity has also been
documented between northern and southern East African
T.b. rhodesiense HAT. However, it is unknown if this is
caused by differences in patient susceptibility to infection,
genetic variation in parasite virulence, or both, as despite
the existence of good molecular tools, previous studies
have involved limited numbers of HAT cases. In this paper
we present extensive clinical data on T. b. rhodesiense cases
and describe robust clinical profiles for three disease foci.
Common presenting symptoms were identified. We also
describe marked differences in disease progression and
severity both between Ugandan and Malawi foci, and
between two Ugandan foci (Tororo and Soroti) giving rise
to three foci-specific clinical phenotypes ranging from a
chronic haemo-lymphatic stage infection in Malawi, to
rapid disease progression and neurological dysfunction in
Soroti and severe neuropathology in Tororo cases. Most
importantly, we have now established clinical focus-
specific phenotypes that will be available to supplement
host and parasite genetics studies to determine their
contribution to HAT disease virulence.
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Serere Health Centre or Nkhotakota hospital. To ensure
consistency in qualitative clinical observations, all staff involved
in this study were trained in the use of a standardised patient
record form. Vital signs were first assessed including body
temperature (fever defined as auricular, oral or axillary
temperature of $38.0uC), radial pulse (normal adult pulse 60–
100 beats per minute) and blood pressure (normal diastolic
pressure 60–90 mmHg, normal systolic pressure 110–
140 mmHg).
Typical non-neurological signs of HAT [30] were recorded
including presence of a chancre, ascites and oedema (severity of
oedema categorised as none, mild or severe). The spleen, liver and
lymph nodes were palpated and any enlargement recorded. Blood
haemoglobin (Hb) was measured to diagnose anaemia by
calculating haematocrit levels from packed cell volume (PCV).
PCV was measured by collecting peripheral blood into a
heparinised capillary tube, centrifuged for 10 minutes at
10,000 rpm in a microhaematocrit centrifuge and the volume of
packed cells read as a proportion of the total volume of blood
expressed as l/l. This value was converted using the conventional
conversion factor: 100 g Hb =6.2 mmol Hb =0.30 l/l haema-
tocrit [31]. Baseline Hb levels vary with age, gender and
pregnancy [32], therefore, we used the criteria by which WHO
define mild anaemia and severe anaemia [33]. Briefly, mild
anaemia was diagnosed as Hb ,110 g/L in children aged 6–
59months and pregnant women $16 years old; Hb,115 g/L in
children aged 5–11years old; Hb,120 g/L in children aged 12–
15 years old and non-pregnant women $16 years old;
Hb,130 g/L in men $16 years old. Severe anaemia was
diagnosed as Hb #60 g/L in all groups.
The Glasgow Coma Score (GCS) [34] was used to assess the
level of neurological dysfunction in each HAT case recruited from
2002 onwards. GCS determines best eye opening, motor and
verbal response (normal value is 15, and a score of #8 indicates
severe impairment of consciousness). Other clinical parameters
that infer CNS involvement were recorded for all cases such as
altered gait (categorised as normal, able to walk if aided or unable
to walk), cranial nerve palsies, tremors, urinary incontinence and
somnolence [30].
HAT staging criteria. Stage of trypanosome infection was
determined in accordance with WHO criteria, late stage infection
diagnosed when trypanosomes are detected in the cerebrospinal
fluid (CSF) or when present in blood and CSF white blood cell
(WBC) count .5/mm
3 [35]. A lumbar puncture was performed
on individuals who were either T. brucei blood positive or
Figure 1. Map of Uganda (green) and Malawi (purple) districts where Sleeping Sickness patients were recruited in this study. The
Soroti focus encompasses Uganda districts 1–3 and the Tororo focus encompasses districts 4–12.
doi:10.1371/journal.pntd.0000906.g001
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characteristic of late stage HAT [30]. Microscopic examination
of CSF using a Neubauer haemacytometer (Hawksley, U.K.)
determined CSF parasitaemia and WBC counts. Double
centrifugation of CSF was performed in Uganda to increase
sensitivity of trypanosome detection [36] in Malawi presence or
absence of T. brucei in CSF was recorded with WBC counts.
Co-infection assessment. 285 HAT patients were screened
for malaria and filariasis as part of the blood examination protocol.
Stool and urine samples were microscopically examined to screen
for hookworm infections and schistosomiasis. All individuals
diagnosed with malaria, filariasis or schistosomiasis were given
treatment but omitted from this study. Cases with hookworm
infections were noted but still were recruited. In the Tororo focus,
six HAT cases were diagnosed with malaria and one with filariasis;
in the Nkhotakota focus two patients presented with malaria co-
infection and one with schistosomiasis, therefore, ten HAT cases
were omitted from this study.
Indicators of infection duration. To evaluate the rate of
disease stage progression it was necessary to estimate the duration
of trypanosome infection. In each case this was achieved by noting
presence of chancre on admission, recording an approximate
duration of illness and when bitten according to HAT patients at
interview. A hypothetical map of disease progression in each focus
was generated by calculating the estimated median post-infection
time from patient interview data for all cases presenting with a
particular clinical sign or symptom of HAT on admission. A
chancre is the first sign of T.b. rhodesiense infection, it develops
within 5–15 days of inoculation and heals within 2–3 weeks
[30,37], therefore, patients presenting with a chancre had an
estimated post-infection time of 19–36 days. Additionally, as a
chancre is often accompanied by swollen local lymph nodes,
prevalence of localised lymphadenopathy was also used to indicate
recent infection.
Treatment. The treatment regimen for early and late stage
T.b. rhodesiense were those used by the National Sleeping Sickness
Control programmes. Briefly, in Uganda early stage patients were
given Suramin (Antrypol: Bayer: 20 mg/kg) and late stage cases
were initially given suramin followed by four series of melarsoprol
(MelB) (Arsobal: Rhone-Poulenc: 3.6 mg/kg). In Malawi early
stage cases were given four doses of suramin followed by one series
of MelB and late stage patients were given two doses of suramin
followed by three series of MelB.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All patients recruited received
written and verbal information explaining the purpose of this study
and gave informed consent. The ethical committees in Uganda
(Ministry of Health), Malawi (College of Medicine) and the UK
(Grampian Joint Ethics Committee) approved all protocols.
Ethical consent forms were designed in English and also translated
into local languages. Consent was given as a signature or a thumb
print after verbal explanation. For those under 16 consent was
given by their legal guardian, and for those whose clinical
condition prohibited full understanding of the recruitment process,
consent was gained from a spouse or other family member. Blood
and CSF analysis was carried out on admission and on discharge
as part of normal diagnostic and follow-up procedures.
Statistical analysis
Data analyses were carried out using Statview and JMP (SAS
Institute, Cary, North Carolina) statistical packages. The distribu-
tion of continuous variables was assessed for normality using the
Shapiro-Wilks W test and Levene’s test for homogeneity of
variance between groups, standard transformations were applied
as appropriate [38]. Parametric statistics were used to analyse
normally distributed continuous data including the unpaired
Student’s t test for variation between groups, the paired t test for
matched groups and analysis of variance (ANOVA) for comparing
more than two groups in conjunction with the Tukey-Kramer
post-hoc test. Non-parametric statistics were used when data was
not normally distributed and could not be transformed, these
included the Mann Whitney U test to compare two groups, the
Wilcoxon signed rank test for matched groups and the Kruskal-
Wallis test when more than two groups were being compared.
Additionally, Spearman’s Rho was used to assess relationships
between continuous variables and Fisher’s exact test was used to
test for associations between discontinuous variables. To address
missing data, the exact number of cases analysed for each
parameter measured is given.
Results
HAT patients
Geographical distribution. The geographical distribution
of 275 HAT patients recruited across three East African foci
during several surveillance periods from January 1998 to
December 2003 is summarised in Table 1. HAT due to
T.b.rhodesiense was found in a large number of districts within the
historic SE Uganda/Kenyan border (Busoga) focus but the highest
number of cases were from Tororo district, thus, this will
henceforth be called the Tororo focus. In E Uganda HAT cases
were concentrated in Soroti district and so will be called the Soroti
focus. Surveillance in C Malawi was restricted to Nkhotakota
district in 2002 and will be called the Nkhotakota focus.
Age and gender. The median age of HAT patients (Table 2)
did not differ between foci (Kruskal-Wallis test, p.0.05).
However, a higher proportion of cases in the Soroti focus were
women and children (,16 years old) (Fisher’s Exact Test,
p#0.01), while most cases were adult males in the Nkhotakota
Table 1. Geographical distribution of HAT patients recruited
during 1998–2003.
Focus Country District No. of HAT cases
Tororo Uganda Tororo 31
Iganga 11
Busia 9
Bugiri 5
Mokono/Buvuma Island 3
Jinja 1
Kenya Teso 10
Busia 1
Bungoma 1
Total 72
Soroti Uganda Soroti 158
Kumi 1
Kaberamaido 1
Total 160
Nkhotakota Malawi Nkhotakota 43
Total 43
doi:10.1371/journal.pntd.0000906.t001
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of exposure to human-infective trypanosomes due to the different
roles within each society for men, women and children. In Soroti
women and children traditionally have a cattle-keeping role, while
in Nkhotakota many adult males work in the nearby wildlife
reserve.
T.b. rhodesiense infection stage diagnosis. In the
Nkhotakota focus HAT patients predominantly presented with
haemo-lymphatic stage infections (Table 2), while in the Uganda
Soroti and Tororo foci the majority of HAT patients were
diagnosed with meningo-encephalitic stage infections (Fisher’s
Exact Test, p,0.0001).
Clinical observations
Non-neurological characteristic signs of HAT. A high
proportion of early stage HAT patients in the Tororo and Soroti
foci presented with chancre (Table 3), this was indicative of recent
infection (19–36 days). Additionally, in Uganda up to 26% late
stage cases presented with chancre demonstrating rapid
progression to meningo-encephalitic infection. In the Nkhotakota
focus, however, no HAT patients presented with chancre or,
according to patient interview information, had ever formed a
chancre at the inoculation site.
Fever was a common presenting symptom in both early and late
stage T. b. rhodesiense infections in the Malawi Nkhotakota focus but
was less frequently observed in Ugandan patients (Fisher’s Exact
Test, p#0.001) (Table 3). However, in interview, the prevalence of
recent fever was extremely high in Ugandan HAT cases suggesting
intermittent waves of fever. Although raised radial pulse was not
observed in Nkhotakota cases and infrequently in Ugandan cases,
other signs of cardiovascular involvement were commonly
recorded in Ugandan T.b. rhodesiense HAT. Low systolic and
diastolic blood pressure were significantly more prevalent in late
stage Tororo HAT patients than those in Soroti and Nkhotakota
Table 2. HAT patient age distribution, gender/age ratio and
stage of infection.
HAT Focus Count
Median age (IQR)
[Range]
% adult male:
female: child*
Late Stage
(%)
Tororo 72 26 (26) [2–75] 43:39:18 86
c
Soroti 160 23 (29) [2–85] 27:43:30
a, c 77
c
Nkhotakota 43 28 (19) [1–84] 60
b:28:12 16
*Child ,16 years old.
aSignificantly higher than Tororo (p,0.05).
bSignificantly higher than Soroti (p,0.05).
cSignificantly higher than Nkhotakota (p,0.05).
doi:10.1371/journal.pntd.0000906.t002
Table 3. Non-neurological signs of HAT in early and late stage infections.
Clinical observations
Tororo focus Soroti focus Nkhotakota focus
Early stage infections n % n % n %
Chancre 10 50
c 37 46
c 36 0
Fever 8 13 37 14 30 50
b
Raised pulse 2 0 31 10 14 0
Low blood pressure systolic/diastolic 2 100/0 24 21/4 26 0/0
Lymphadenopathy 2 100 26 27 29 10
Splenomegaly 2 0 29 7 31 36
b
Hepatomegaly 2 0 29 0 30 40
b
Ascites 2 0 30 0 29 0
Anaemia normal:mild:severe 10 10:80:10 37 38:57:5 25 16:68:16
Oedema normal:mild:severe 2 50:50:0 33 70:24:6 32 75:16:9
Late stage infections n % n % n %
Chancre 61 17
c 119 26
c 70
Fever 58 20 119 14 4 100
a, b
Raised pulse 27 11 81 15 6 0
Low blood pressure systolic/diastolic 25 72/28
b, c 65 37/8 6 0/0
Lymphadenopathy 23 30 64 48 6 0
Splenomegaly 27 33
b 69 15 6 0
Hepatomegaly 25 16
b 67 3 6 0
Ascites 27 4 78 9 5 0
Anaemia normal:mild:severe 62 14:81:5 123 4:91
a:5 4 25:75:0
Oedema normal:mild:severe 26 85:15:0 76 42:47
a:11 6 67:33:0
n represents the number of patients for which presence or absence of each clinical observation was recorded, prevalence of each parameter is expresseda sa
percentage of n.
aSignificantly higher than Tororo (p,0.05).
bSignificantly higher than Soroti (p,0.05).
cSignificantly higher than Nkhotakota (p,0.05).
doi:10.1371/journal.pntd.0000906.t003
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frequently recorded in Soroti late stage cases than those in Tororo
(Fisher’s Exact Test, p=0.01) (Table 3).
Abdominal palpation revealed splenomegaly and hepatomegaly
were common signs of HAT in Nkhotakota focus early stage HAT
patients, this was particularly so in children (,16 years old)
(Fisher’s Exact Test, p,0.05). However, prevalence of both was
significantly lower in the Soroti focus (Fisher’s Exact Test,
p#0.01), and not observed in the small number of early stage
Tororo cases. In late stage HAT, however, splenomegaly and
hepatomegaly were significantly more frequently observed in
Tororo than Soroti focus cases (Fisher’s Exact Test, p,0.05)
(Table 3). Occurrence of hepatomegaly correlated with spleno-
megaly in Sleeping Sickness patients in all foci (Fisher’s Exact Test,
p,0.0001). Ascites was only observed in a small number of late
stage HAT cases in Ugandan foci.
Mild anaemia was the most common presenting clinical sign of
both early and late stage HAT in all foci (Table 3). Mild anaemia
was more prevalent in late stage cases in the Soroti focus
compared to Tororo focus cases (Fisher’s Exact Test, p =0.01).
Severe anaemia was not frequently diagnosed, but was most
prevalent in early stage patients in the Nkhotakota focus.
Neurological signs characteristic of HAT. A rapid onset of
neurological dysfunction was observed in Soroti haemo-lymphatic
stage HAT cases. Comparison of prevalence of neurological signs
of HAT between early stage Soroti and Nkotakota cases revealed
Soroti focus cases displayed a higher prevalence of altered gait on
admission (Fisher’s Exact Test p,0.05), tremors (Fisher’s Exact
Test, p,0.001), cranial nerve palsies (Fisher’s Exact Test,
p,0.01), urinary incontinence and somnolence (Fisher’s Exact
Test, p,0.0001) (Table 4). It was not possible to compare Tororo
focus early stage HAT due to the small group size.
In meningo-encephalitic stage cases cranial neuropathies and
tremors were more prevalent in Soroti than Tororo focus cases
(Fisher’s Exact Test, p=0.001, p,0.0001 respectively), while
abnormal GCS was most frequently recorded in Tororo focus
patients (Fisher’s Exact Test, p,0.001) (Table 4). In addition, a
higher prevalence of coma was observed in Tororo than Soroti
focus late stage patients (Fisher’s Exact Test, p,0.05). The
proportion of patients presenting with altered gait, somnolence
and urinary incontinence continued to be high in Soroti but
prevalence in Tororo and Nkhotakota foci increased, therefore, no
significant differences in these clinical parameters was detected
between foci.
Interestingly, a higher prevalence of signs of neurological
involvement was recorded in children in Uganda HAT foci.
Altered gait was more frequently observed in early stage patients
under 16 in the Soroti focus and in late stage Tororo focus cases
(Fisher’s Exact Test, p#0.02), urinary incontinence was also more
prevalent in children with late stage infections in the Tororo focus
(Fisher’s Exact Test, p,0.05), and severe neurological dysfunction
(GCS #8) was more commonly recorded in children with late
stage infections in both Uganda foci (Fisher’s Exact Test, p,0.05),
in fact all cases presenting with GCS #8 in the Tororo and Soroti
foci were male and #12 years old.
Mortality. Mortality rates did not significantly differ between
HAT foci (Table 4) and there was no correlation with patient age.
In Nkhotakota one of the early stage fatalities occurred after
developing bacterial meningitis, the other occurred after HAT
treatment of an unknown cause, while one meningo-encephalitic
Table 4. Neurological signs & mortality rates in early and late stage HAT infections.
Clinical observations
Tororo focus Soroti focus Nkhotakota focus
Early stage infections n % n % n %
Altered Gait normal:aided:unable 2 100:0:0 33 36:46
c:18 28 65:21:14
Tremors 2 0 33 61
c 30 17
Cranial neuropathies 2 0 33 30
c 31 3
Urinary Incontinence 2 0 31 16 30 7
Somnolence 2 0 33 58
c 25 4
GCS ,15 2 0 33 12 32 3
GCS #8 2 0 33 0 32 0
Mortality 10 0 37 0 36 6
Late stage infections n % n % n %
Altered Gait normal:aided:unable 26 54:31:15 83 47:35:18 6 50:17:33
Tremors 25 0 84 67
a 63 3
Cranial neuropathies 26 0 81 31
a 61 7
Urinary Incontinence 27 26 83 17 6 17
Somnolence 26 46 84 54 4 25
GCS ,15 27 52
b 84 14 6 33
GCS #82 7 1 0
b 84 3 6 3
Mortality 62 11 123 6 7 14
n represents the number of patients for which presence or absence of each clinical observation was recorded, prevalence of each parameter is expresseda sa
percentage of n.
aSignificantly higher than Tororo (p,0.05).
bSignificantly higher than Soroti (p,0.05).
cSignificantly higher than Nkhotakota (p,0.05).
doi:10.1371/journal.pntd.0000906.t004
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patients (2 Tororo, 2 Soroti) died before MelB was administered,
three of which were recruited with severe neurodegeneration
(GCS 9–13). However, seven late stage HAT cases (4 Tororo, 3
Soroti) died during or just after the first two series of MelB
treatments suggesting possible arsenical encephalopathy [30], and
a further two patients died after treatment. There is no
information on time of death for one Soroti case. The clinical
symptoms found to be significantly associated with fatal outcome
across foci included oedema, altered gait, urinary incontinence
and abnormal GCS (Fisher’s Exact Test, p,0.001, p,0.001,
p,0.05 & p=0.001 respectively).
Common clinical observations in T.b. rhodesiense
infection
To establish which clinical observations were indicative of early
and late stage T.b. rhodesiense infection the most frequently observed
signs and symptoms in each focus (present in more than one third
of all HAT patients examined on admission) are summarised in
Table 5. Mild anaemia was commonly diagnosed in both haemo-
lymphatic stage and meningo-encephalitic stage T.b. rhodesiense
infections in all three foci. In both Ugandan foci chancre was a
frequent presenting sign of early stage HAT, however, Soroti early
stage HAT was characterised by tremors, somnolence and walking
only when aided pointing to early onset neuropathology, while
Nkhotakota early stage HAT was characterised by hepatomegaly,
splenomegaly and fever. Although somnolence was indicative of
late stage HAT in both Ugandan foci only, severe neurological
dysfunction was particularly prevalent in Tororo focus HAT.
Clear differences in HAT disease profiles, therefore, were observed
between distant HAT foci and those within close proximity.
T.b. rhodesiense infection duration and rate of stage
progression
Estimated duration of infection. According to HAT
patient interview data (Table 6) early stage cases in the
Nkhotakota focus had been infected for longer (median 30 days)
than Soroti focus patients (median 23 days) (ANOVA, p=0.01).
Furthermore, after an estimated post-infection time of $90 days a
significantly larger proportion of Nkhotakota cases had not
progressed to late stage infection (Fishers Exact test, p,0.01)
suggesting prolonged haemo-lymphatic infection in this focus.
Most rapid progression to late stage infection occurred in Soroti
focus HAT patients (Table 6), this was significantly shorter than
both in Tororo focus patients and Nkhotakota focus patients
(ANOVA, p,0.001 & 0.01 respectively), and was supported by a
higher prevalence of chancre in Soroti focus late stage cases.
Furthermore, a significantly higher percentage of Tororo late stage
cases had been infected for $90 days than observed in Soroti
(ANOVA, p,0.01). Thus, T.b. rhodesiense infection in the
Nkhotakota focus did not cause chancre formation and
progression to CNS infection occurred on average 5 months
after infection. Within Uganda, however, HAT followed a more
aggressive disease course. This was particularly apparent in Soroti
focus cases where meningo-encephaltic stage infection occurred in
less than 2 months.
Disease progression. The estimated duration of T.b.
rhodesiense infection, according to patient interview information,
has been used to map the time at which each clinical HAT
symptom recorded was present in Tororo, Soroti and Nkhotakota
foci patients thereby generating a summary of T.b. rhodesiense HAT
disease progression as schematically represented in Figure 2.
Non-neurological signs of Sleeping Sickness generally manifest-
ed at an earlier post-infection time in Soroti focus patients than
Tororo focus cases (Figure 2) These included chancre (Student’s t-
test, p,0.05), mild anaemia (ANOVA, p=0.001) and mild
oedema (ANOVA, p,0.05). Furthermore fever, swollen lymph
nodes, splenomegaly and severe anaemia were all observed in
Soroti focus cases before Tororo HAT patients but post-infection
times did not significantly differ. In Nkhotakota focus patients the
observation times of non-neurological signs of HAT did not
Table 5. The most prevalent (in .1/3 cases) clinical
observations in T.b. rhodesiense HAT.
Early stage HAT characteristics Late stage HAT characteristics
Clinical observation n % Clinical observation n %
Tororo focus Tororo focus
Lymphadenopathy 2 100 Mild anaemia 64 81
Low systolic BP 2 100 Low systolic BP 25 72
Mild anaemia 10 80 GCS,15.82 7 5 2
Mild oedema 2 50 Somnolence 26 46
Chancre 10 50
Soroti focus Soroti focus
Tremors 33 61 Mild anaemia 122 91
Somnolence 33 58 Tremors 84 67
Mild anaemia 37 57 Somnolence 84 54
Chancre 37 46 Lymphadenopathy 64 48
Gait aided 33 45 Mild oedema 76 47
Low systolic BP 65 37
Gait aided 83 35
Nkhotakota focus Nkhotakota focus
Mild anaemia 25 68 Fever 4 100
Fever 30 50 Mild anaemia 4 75
Hepatomegaly 30 40
Splenomegaly 31 36
doi:10.1371/journal.pntd.0000906.t005
Table 6. Estimated HAT infection duration and rate of stage
progression using patient interview data.
HAT Focus
Estimated post-infection
time Days
Median (IQR) [Range]
Estimated infection
duration $90 days
(%)
Early stage
Tororo n=10 26 (43) [5–120] 12
Soroti n=37 23 (26) [2–90] 3
Nkhotakota n=36 30 (99) [10–330]
b 33
Late stage
Tororo n=62 82 (111) [13–366]
b 47
b
Soroti n=123 50 (53) [6–240] 24
Nkhotakota n=7 135 (150) [30–240]
b 67
aSignificantly higher than Tororo (p,0.05).
bSignificantly higher than Soroti (p,0.05).
doi:10.1371/journal.pntd.0000906.t006
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hepatomegaly manifested at noticeably later post-infection times in
Malawi and was significantly correlated with haemo-lymphatic
stage infection duration (Mann Whitney U test, p,0.01).
Signs of neurological dysfunction were observed earliest in
Soroti focus HAT patients. In particular, altered gait was observed
at an earlier post-infection time than Tororo and Nkhotakota
HAT patients (ANOVA, p,0.05 & 0.01 respectively). Tremors
Figure 2. Map of T.b. rhodesiense HAT disease progression. Estimated post-infection time (weeks), from patient interview data, at which each
clinical observation was recorded in Tororo, Soroti and Nkhotakota foci HAT patients on admission. a. Significantly earlier than Tororo (p,0.05). b.
Significantly earlier than Soroti (p,0.05). c. Significantly earlier than Nkhotakota (p,0.05).
doi:10.1371/journal.pntd.0000906.g002
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patients (Student’s t-test, p=0.01) and were not observed in
Tororo focus cases. All other neurological signs of HAT recorded
(cranial neuropathies, urinary incontinence, somnolence, abnor-
mal GCS) were also observed first in Soroti focus HAT patients
but this did not significantly differ from other foci. In addition,
cases with a fatal outcome had shorter infection duration times in
Ugandan foci (both 90 days) than Nkhotakota focus cases (195
days).
This data establishes three different disease progression profiles
for T.b. rhodesiense HAT indicative of marked differences both
between northern and southern East African foci and between
Ugandan foci. T.b. rhodesiense HAT follows a particularly acute
disease course in the Soroti focus with CNS involvement apparent
very early in infection and more rapid progression to late stage
infection. In Tororo, progression to late stage infection was slower
than in Soroti, however, late stage HAT patients manifested with
the most severe neurological dysfunction Furthermore, HAT
patients in the Tororo focus presented with neurological symptoms
before Nkhotakota cases where a chronic disease course was
observed characterised by a prolonged haemo-lymphatic stage of
infection associated with hepato- and splenomegaly.
Parasite burden
Parasitaemia (Table 7) did not significantly differ in early stage
HAT cases between Soroti and Tororo Ugandan foci (no
parasitaemia data was available for Nkhotakota focus cases).
Parasitaemia was significantly higher, however, in early stage
compared to late stage infections in both Ugandan foci (Mann
Whitney U test, p,0.05 & 0.01 respectively). CSF parasite levels
did not significantly differ between Ugandan foci (no data was
available for Nkhotakota cases). CSF WBC counts were
significantly elevated in Tororo late stage cases compared to
Soroti patients (Mann Whitney U test, p,0.0001, (Nkhotakota
cases also presented with higher CSF WBC counts but this was not
significant due to the low number of late stage cases). CSF WBC
count was positively correlated to CSF parasite levels in late stage
HAT cases in Tororo (Spearman’s Rho 0.312, p,0.05) and Soroti
foci (Spearman’s Rho 0.532, p,0.0001), however, only high CSF
parasite levels was found to be associated with a fatal outcome in
both Ugandan foci (Mann Whitney U test, p,0.01).
Prevalence of co-infections
HAT cases with malaria, schistosomiasis and filariasis were
excluded from this study, however, those with hookworm co-
infection were recruited. Hookworm co-infection was not observed
in the Nkhotakota focus and only 1% of Soroti focus HAT cases
presented with hookworm infection. In Tororo focus HAT cases
hookworm was not highly prevalent (13%), however, it was more
frequently observed than in other foci (Fishers Exact Test,
p,0.0001). Hookworm co-infection was not correlated with
HAT stage of infection, infection duration or fatal outcome and
did not account for the high prevalence of anaemia observed in
HAT cases (Table 3).
Discussion
The presenting clinical signs and symptoms of T.b. rhodesiense
HAT can be relatively non-specific, however, typically the first
sign of infection is a local acute skin inflammatory response called
a trypanosomal chancre at the inoculation site which appears
within 5–15 days, is usually 2–5 cm in diameter [37] and lasts for
2–3 weeks. Haemo-lymphatic system involvement begins 1–3
weeks after infection and is typically accompanied by fever,
lymphadenopathy, hepatomegaly, splenomegaly, skin rash, prur-
itis, tachycardia, weight loss, general malaise, and weakness
[30,39]. The meningo-encephalitic stage of infection commences
when trypanosomes cross the blood brain barrier (BBB) and
invade the CNS. It is associated with psychiatric, motor and
sensory disorders, and the classic reversal of sleep patterns leading
eventually to coma and death [1]. The transition from early to late
stage in T.b. rhodesiense infection can occur within a few weeks,
indicative of an acute disease, often before neurological involve-
ment becomes pronounced [40,41]. This ‘typical’ disease profile
for T.b. rhodesiense HAT, however, varies enormously between foci.
In this study of 275 T.b. rhodesiense HAT cases in three East African
foci (Tororo and Soroti foci, E Uganda; Nkhotakota focus, C
Malawi) mild anaemia was the only common (.1/3 cases)
presenting clinical observation. Anaemia is a characteristic feature
of bovine trypanosomiasis [42] and experimental T. brucei
infections in mice [43], however, in HAT anaemia has generally
not been recorded as one of the main symptoms of human T.b.
rhodesiense infection [30,44] or has been attributed to other parasitic
infections or malnutrition [45,46,47]. The high rate of anaemia in
Table 7. Blood parasitaemia, CSF parasite levels and CSF WBC counts in HAT patients.
HAT focus
Wet film parasitaemia
per 10 fields (400x)
Median (IQR) [Range]
CSF Parasite load
per mm
3
Median (IQR) [Range]
CSF WBC count
per mm
3
Median (IQR) [Range]
Early stage n
Tororo 10 13 (40) [0–840]
d
Soroti 11 3 (82) [0–400]
d
Nkhotakota 0 ND
Late stage n n n
Tororo 56 0 (3) [0–40] 49 1 (5) [0–69] 58 74 (110) [6–704]
b
Soroti 52 1 (6) [0–400] 109 2 (5) [0–1440] 116 35 (67) [2–938]
Nkhotakota 0 ND 0 ND 4 81 (193) [248]
n represents the number of HAT patients for which parasite burden and CSF WBC counts were recorded.
bSignificantly higher than Soroti (p,0.05).
dSignificantly higher than late stage infection (p,0.05).
doi:10.1371/journal.pntd.0000906.t007
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patients in this study) has been previously reported [48]. Marked
differences in other HAT presenting signs and symptoms between
study sites allowed us to establish T.b. rhodesiense foci-specific
clinical profiles (Table 5).
Early stage HAT cases in two Ugandan foci typically presented
with a chancre, in contrast, none of the Nkhotakota focus patients
developed a lesion at the tsetse fly bite site (Table 3). Lack of
chancre development may be associated with lower parasite
virulence as it occurs more frequently in T.b. rhodesiense infections
than the more chronic T.b. gambiense disease [49,2], however, it
may also be associated with patient ethnicity and previous
exposure to T.b. rhodesiense as chancre has been more commonly
reported in European cases with both T.b. rhodesiense and T.b.
gambiense infections [50,44,7,49,4]. Instead Nkhotakota early stage
HAT cases typically presented with fever, splenomegaly and
hepatomegaly. Splenomegaly, caused by increased inflammation
with an accumulation of activated macrophages in splenic
sinusoids, is described as a symptom characteristic of both early
stage T.b. rhodesiense and T.b. gambiense HAT [39,30]. The high
prevalence of hepatosplenomegaly in haemo-lymphatic stage
Nkhotakota cases (Table 3 & 5), similar to that observed in T.b.
gambiense infections [49,41], could indicate a more pronounced
immune response to T.b. rhodesiense infection, which may be
associated with improved control leading to the chronic disease
course typically observed in this focus. This would be consistent
with observations of pathogenesis in malaria where spleen size and
the rate of splenomegaly increase with age and immunity, previous
exposure to P. falciparum can alter spleen response in malaria, and
splenomegaly is associated with both protection [51] and a better
prognosis in cerebral malaria [52].
The effects of T.b. gambiense infection on the cardiovascular
system have been well described, with a high prevalence of
electrocardiogram (ECG) changes recorded [53]. Less is known in
T.b. rhodesiense HAT, however, there is some evidence for ECG
alterations during infection [54], histological examinations have
shown myocardinal degeneration and interstitial haemorrhage
[55], and infectious perimyocarditis can be more severe which can
lead to a fatal outcome [55,56]. Indeed, in some studies, cardiac
involvement is thought to cause death before neurological
deterioration manifests [40], [41]. Previously recorded symptoms
of cardiac involvement include tachycardia [39] and generalised
oedema, especially of the extremities and the face, caused by
increased capillary fragility and permeability [57], which has been
associated with congestive heart failure in T.b. rhodesiense HAT
[58]. In this study, tachycardia was rarely recorded in haemo-
lymphatic stage cases, although generalised mild oedema was
highly prevalent in late stage Soroti cases (Table 3 & 5). In
addition, low systolic blood pressure was frequently observed in
late stage HAT cases in both Ugandan foci, which can lead to
organ failure. However, in Soroti the haemo-lymphatic stage HAT
was uniquely distinguished by very early onset neurological
involvement (Table 4 & 5). Motor system involvement was
frequently observed in Soroti early stage cases presenting as
extrapyramidal disorders such as limb and tongue tremors,
cerebellar ataxia leading to alteration in gait, and characteristic
sleep disturbances including uncontrollable urges to sleep and
classic reversal of the sleep-wake cycle with daytime somnolence
alternating with nocturnal insomnia [59,44,30]. This is particu-
larly interesting as neurological dysfunction has not previously
been clearly documented in African HAT cases prior to detection
of trypanosomes in the CSF. In 84% of the early stage Soroti focus
HAT cases, for which we have recorded neurological observations
(Table 4), CSF double-centrifugation was performed before CSF
microscopic examination thereby increasing the sensitivity of
parasite detection [27] both on admission and discharge. All early
stage cases were blood and CSF negative for parasites after
suramin treatment, and CSF WBC counts were #5/mm
3 in all
cases on discharge with the exception of one patient (CSF WBC 6/
mm
3) suggesting these were indeed haemo-lymphatic stage
infections and not misdiagnosed late stage cases. In Uganda
HAT cases are followed up at 3, 6, 12 and 24 months but the
follow up rate is less than half. Unfortunately we do not have
follow-up records for these specific cases, however, patients are
only discharged if neurological features are absent, and it is
exceptional to receive patients returning with relapsed infections
and there is no empirical evidence to indicate that there are deaths
in the community that may be associated with relapses (M.Odiit,
Unpublished observations). In T.b. gambiense early stage patients
with neurological signs would be treated with the late stage drug
regimen due to the high relapse rates when treated with suramin
and pentamidine [60]. CNS involvement has been previously
reported in early stage HAT infections in non-African patients
[44], suggesting host genotype/inflammatory response plays a role
in the onset of neurological dysfunction. Unfortunately the low
number of Tororo focus haemo-lymphatic stage HAT cases did
not allow us to establish a robust early stage clinical profile for this
focus.
Meningo-encephalitic stage T.b. rhodesiense infection is typically
associated with severe neurological deterioration, leading to
somnolence, coma and death. This was most apparent in the
Tororo focus where late stage cases displayed severe neurological
dysfunction on admission. This was assessed using GCS, which
measures alterations in patient motor, verbal and eye opening
responses [34]. Abnormal GCS and somnolence were character-
istic symptoms of late stage HAT in Tororo (Table 4 & 5). Soroti
late stage HAT cases also commonly presented with symptoms
indicative of neurological dysfunction including somnolence,
tremors and walking only if aided (Table 4 & 5). In late stage
Nkhotakota cases although tremors, altered gait and somnolence
were recorded in a third or less cases, the number of late stage
cases recruited in this focus were low.
Distinct differences in duration of infection and the rate of stage
progression in HAT were also established between patients from
foci in Uganda and Malawi, and between cases from different
Ugandan foci. In the Nkhotakota focus of Malawi T.b. rhodesiense
HAT manifested as a chronic long-term disease. Overwhelmingly
HAT patients presented with haemo-lymphatic stage infections
(Table 2), no chancre formed at the bite site and regional
lymphadenopathy were rarely observed (both signs characteristic
of early infection). We also used patient interview data to estimate
post-infection times. Although interview data can be inaccurate
and subject to bias, it is the only method available in field studies of
HAT, and was supported both by disease stage diagnosis and
clinical indicators of early infection. This data showed estimated
early stage infection duration was significantly longer in Nkhota-
kota cases than observed in the Soroti focus, with a third infected
for more than 3 months without progressing to meningo-
encephalitic stage infection (Table 6). Furthermore, prolonged
haemo-lymphatic stage infection in Nhkotakota was associated
with splenomegaly. These observations are more characteristic of
T.b. gambiense infections and consistent with the previously
described chronic T.b. rhodesiense HAT in Zambia [4,5,6,7]. In
contrast, T.b rhodesiense HAT followed a more acute disease course
in Uganda. The prevalence of meningo-encephalitic stage
infections was extremely high in both Ugandan foci (Table 2)
despite shorter estimated infection duration periods than Nkho-
takota cases (Table 6). This rapid progression to late stage infection
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lymphadenopathy in late stage cases in both Ugandan foci
(Table 3) in conjunction with signs and symptoms of severe
neurological involvement (Table 4). Differences in disease
progression between Ugandan foci, only 150 km apart, were also
apparent, with Tororo late stage cases estimated to have been
infected for a significantly longer period of time than Soroti cases
(Table 6). This would suggest that T.b. rhodesiense penetration of the
CNS is a more rapid process in Soroti than Tororo HAT cases,
however, these infection duration differences must be interpreted
with some caution. Previous work analysing a subset of Soroti and
Tororo HAT cases presented here did not show any significant
difference in infection duration between these foci [21]. Compar-
ison of blood and CSF parasite levels (Table 7) between Ugandan
foci did not significantly differ suggesting distinct HAT disease
phenotypes established were not due to parasite burden. However,
CSF WBC counts were significantly higher in Tororo late stage
cases than those from the Soroti focus (Table 7), which may be
indicative of a better host immune response to infection in Tororo
cases. In addition, to determine robust clinical profiles in natural
T.b. rhodesiense infections it is important to consider the impact of
co-infections, thus, HAT cases with highly prevalent diseases such
as malaria, filariases or schistosomiasis were not recruited, and
those with hookworm infections showed no association with
anaemia, HAT severity or progression. However, it is also
important to mention human immunodeficiency virus (HIV)
prevalence. By the end of 2003, 14% of the adult population in
Malawi and 4% of the adult population in Uganda were infected
with an estimated 84,000 and 78,000 annual deaths from acquired
immune deficiency syndrome (AIDS) respectively [61]. HAT
patient HIV status was not determined in this study, therefore, it
cannot be ruled out as a confounding factor in HAT disease
severity. However, the higher HIV prevalence recorded in
Malawi, where HAT is characterised as a more chronic disease
than Uganda, at this time suggests HAT focus-specific clinical
phenotypes are not influenced by HIV co-infection.
Concluding remarks
Overall, a comparison of clinical HAT profiles between foci
established marked differences in disease severity between Uganda
and Malawi demonstrating that T.b. rhodesiense HAT manifests as a
chronic disease in Malawi with a low prevalence of neurological
symptoms. Within Uganda, HAT is an acute disease with marked
neurological involvement contrasting with the clinical profiles
previously documented in SE Uganda. In addition, in Soroti a
more aggressive disease course was observed with extremely early
onset neurological involvement, although neurological deteriora-
tion associated with the final stages of HAT were more frequently
observed in late stage patients in the Tororo focus.
Establishing distinct clinical phenotypes in different HAT foci
can improve disease management by focusing control and
surveillance in regions where human disease progression and
severity are most extreme. It is now critical to determine the
mechanisms involved in causing this clinical diversity.
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